GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma

Join Pharma | Login

	Editorial


	SUPREME COURT’S INTERVENTION NEEDED
	Wednesday, May 14, 2025
	Availability of drugs for rare diseases or orphan diseases at reasonably affordable prices has been a major issue the country, for that matter the entire world, has been facing for a long time now.
	Past Editorial...

TODAY'S NEWS


12:00 [IST]	GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma
11:00 [IST]	Monash University and Peninsula Health develop AI method to improve dementia diagnosis
10:00 [IST]	Taiwan FDA approves Chugai Pharma’s PiaSky for subcutaneous treatment of patients with paroxysmal nocturnal hemoglobinuria
09:00 [IST]	JSAI demands Odisha govt to look into growing kidney cases and patient deaths

more news >>

TOP NEWS


08:00 [IST]	Pharmaceuticals exports grew 2.37 per cent in April 2025
08:00 [IST]	Organisers of 74th IPC buoyant to attract over 12,000 delegates driven by its theme ‘AI & Technology in Pharma’
08:00 [IST]	NABL introduces dedicated software to help labs adopt QR Code and ULR authentication system
08:00 [IST]	Kerala poised to become global leader in medical devices and ancillary industries in next 5 years: Dr Satheesh Kumar
08:00 [IST]	DGFT amends import norms for Di-octyl phthalate to enhance export efficiency
08:00 [IST]	Pharma sector reported steady growth of 10% annually in last five years: Centre

more news >>

YESTERDAY'S NEWS


18:00 [IST]	Neutron Therapeutics & Helsinki University Hospital treat first head and neck cancer patients using accelerator-based boron neutron capture therapy
17:15 [IST]	Cytecare highlights at vital role of Oncoanesthesia CANCON 2025
17:00 [IST]	Acadia Pharma gets favourable ruling from Delaware District Court in Nuplazid formulation patent litigation
16:45 [IST]	Venus Remedies joins United Nations Global Compact, reinforcing commitment to sustainable global healthcare
16:00 [IST]	Bristol Myers Squibb gets European nod for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by adjuvant Opdivo for resectable, high-risk NSCLC with PD-L1 expression =1%
14:40 [IST]	Nearly 30% of India’s adult population under the age of 40 is affected by hypertension or prehypertension, Dr Preetha Reddy

more news >>

INTERVIEW


All DIs in TN are fully competent to inspect manufacturing units as per Revised Schedule M: MN Sridhar
MN Sridhar, director of the Tamil Nadu Drugs Control Department

Past Interviews...

	What's New?

USFDA Warning Letters Recently Posted For March 2025 USFDA Warning Letters Recently Posted For February 2025 Mephenamic Acid 250mg And Dicyclomine 20mg Tab Triamcinolone 40 Mg/ml Inj. Ondansetron 2mg/ml

Opinion Poll

Will the introduction of Revised Schedule M by Union Health Ministry solve the issue of quality of Indian drugs?

YesNoCan't Say

View Past Poll

Corporate

Special Features

Features

Chronicle Pharmabiz Specials

Forthcoming Events

TENDERS & PROJECTS

	Tenders & Enquiries
	Pharma Projects

CORPORATE

	Company Profile
	Corporate Results
	Corporate X-ray
	Pharmabiz Studies of Top Companies

US FDA UPDATE

EXPORT & IMPORT

	Drug Export Procedures
	Drug Units With WHO GMP Certification
	Pharma Export Data
	Import Reg. Update

PHARMA LAWS & DOCUMENTS

LIST OF LABS & GOVT. BODIES

	Govt Recognised In-House R&D Units
	AICTE Boards & Committees
	List of Indian CROs
	List of CROs (International)
	Govt & approved labs of India
	List of State Drugs Controllers